Drugs / HS-20090
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05777109 | Apr 2023 → Apr 2024 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04494373 | Sep 2020 → Jun 2021 | metastatic carcinoma in the bone | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-23 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results AUTHORITATIVE NEWS｜HANSOH PHARMA'S RANKL INHIBITOR PK COMPARISON STUDY RESULTS WERE RECOGNIZED BY THE INTERNATIONAL PROFESSIONAL JOURNAL EOID hspharm.com ↗
The results showed that HS-20090 was highly similar to Xgeva in terms of PK, PD, safety and immunogenicity, reflecting its high level of clinical value. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-23 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | AUTHORITATIVE NEWS｜HANSOH PHARMA'S RANKL INHIBITOR PK COMPARISON STUDY RESULTS WERE RECOGNIZED BY THE INTERNATIONAL PROFESSIONAL JOURNAL EOID hspharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05777109 ↗ |
| Modality | Monoclonal antibody | “A human IgG2 monoclonal antibody with affinity and specificity for human RANKL” NCT05777109 ↗ |
| Route | Subcutaneous | “Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day” NCT05777109 ↗ |